Literature DB >> 33782812

LncRNA SNHG6 promotes breast cancer progression and epithelial-mesenchymal transition via miR-543/LAMC1 axis.

You-Quan Wang1, Guo Huang2, Juan Chen3, Hong Cao4, Wen-Ting Xu4.   

Abstract

PURPOSE: Breast cancer (BC) is the most prevalent cancer in women with an estimated incidence of 10% and the leading cause of mortality due to its heterogenous property and high metastasis rate. Development of novel therapy is very necessary and requires an understanding of molecular mechanisms. We investigated the function of SNHG6/miR-543/LAMC1 axis in BC.
METHODS: Human BC tissues were obtained from diagnosed patients. BC cell lines and normal breast cells were used. QRT-PCR and Western blotting were employed to measure expression levels of SNHG6, miR-543, LAMC1, EMT-related proteins, and PI3K/AKT pathway. Dual-luciferase assay was performed to validate interactions of SNHG6/miR-543 and miR-543/LAMC1. Colony formation assay, flow cytometry, scratch wound healing assay, and transwell assay were utilized to assess the proliferation, apoptosis, migration, and invasion of BC cells. Nude mouse xenograft model was used the evaluate the function of SNHG6/miR-543 in tumor growth in vivo.
RESULTS: SNHG6 and LAMC1 were elevated, but miR-543 was reduced in BC tissues and cells. SNHG6 interacted directly with miR-543, while miR-543 targeted LAMC1. Knockdown of SNHG6 suppressed BC cell proliferation, migration, invasion, EMT, and PI3K/AKT pathway, but promoted cell apoptosis, while miR-543 inhibitor or overexpression of LAMC1 reversed those effects. Overexpression of LAMC1 also blocked the effects of miR-543 on BC cell proliferation, migration, invasion, and EMT. Knockdown of SNHG6 restrained BC growth in vivo, while miR-543 inhibitor inhibited that suppression.
CONCLUSION: SNHG6 promoted EMT and BC cell proliferation and migration by acting as a miR-543 sponge and disinhibiting LAMC1/PI3K/AKT pathway. SNHG6/miR-543/LAMC1 axis could serve as candidates for the development of therapeutic strategies for BC.

Entities:  

Keywords:  Breast cancer; EMT; LAMC1; MiR-543; SNHG6

Mesh:

Substances:

Year:  2021        PMID: 33782812     DOI: 10.1007/s10549-021-06190-y

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  11 in total

Review 1.  Breast intervention and breast cancer treatment options.

Authors:  Olive Peart
Journal:  Radiol Technol       Date:  2015 May-Jun

2.  Roles of long non-coding RNAs in colorectal cancer tumorigenesis: A Review.

Authors:  Halima Siddiqui; Ayat Al-Ghafari; Hani Choudhry; Huda Al Doghaither
Journal:  Mol Clin Oncol       Date:  2019-05-31

3.  MicroRNA-543 acts as an oncogene by targeting PAQR3 in hepatocellular carcinoma.

Authors:  Lei Yu; Luting Zhou; Yu Cheng; Lei Sun; Jian Fan; Jinlong Liang; Mujie Guo; Ning Liu; Liying Zhu
Journal:  Am J Cancer Res       Date:  2014-11-19       Impact factor: 6.166

Review 4.  Emerging roles of lncRNA in cancer and therapeutic opportunities.

Authors:  Ming-Chun Jiang; Jiao-Jiao Ni; Wen-Yu Cui; Bo-Ya Wang; Wei Zhuo
Journal:  Am J Cancer Res       Date:  2019-07-01       Impact factor: 6.166

5.  Long non-coding RNA LINC00628 suppresses the growth and metastasis and promotes cell apoptosis in breast cancer.

Authors:  D-Q Chen; X-D Zheng; Y Cao; X-D He; W-Q Nian; X-H Zeng; X-Y Liu
Journal:  Eur Rev Med Pharmacol Sci       Date:  2017-01       Impact factor: 3.507

6.  MiR-543 functions as tumor suppressor in ovarian cancer by targeting TWIST1.

Authors:  Q Yu; Z Zhang; B He; H Wang; P Shi; Y Li
Journal:  J Biol Regul Homeost Agents       Date:  2020 Jan-Feb       Impact factor: 1.711

Review 7.  lncRNA involvement in hepatocellular carcinoma metastasis and prognosis.

Authors:  Maryam Abbastabar; Mohammad Sarfi; Abolfazl Golestani; Ehsan Khalili
Journal:  EXCLI J       Date:  2018-09-04       Impact factor: 4.068

8.  miR‑543 acts as a novel oncogene in oral squamous cell carcinoma by targeting CYP3A5.

Authors:  Liping Wang; Weihong Chen; Jun Zha; Yongyong Yan; Yongxiang Wei; Xili Chen; Xinxin Zhu; Linhu Ge
Journal:  Oncol Rep       Date:  2019-07-11       Impact factor: 3.906

9.  LncRNA SNHG6 inhibits cell proliferation and metastasis by targeting ETS1 via the PI3K/AKT/mTOR pathway in colorectal cancer.

Authors:  Su Meng; Zhao Jian; Xiaofei Yan; Jibin Li; Rui Zhang
Journal:  Mol Med Rep       Date:  2019-07-19       Impact factor: 2.952

Review 10.  Long non‑coding RNAs in lung cancer: Regulation patterns, biologic function and diagnosis implications (Review).

Authors:  Lin Jiang; Zheng Li; Ranran Wang
Journal:  Int J Oncol       Date:  2019-07-29       Impact factor: 5.650

View more
  4 in total

1.  LncRNA SNHG6 inhibits autophagy of gastric carcinoma cells via PI3K/AKT/mTOR signaling pathway.

Authors:  Wenliang Chen; Zhuo Li; Junfang Duan; Yingtao Liu; Changzhong Fang; Zihao Bai
Journal:  Am J Transl Res       Date:  2022-05-15       Impact factor: 3.940

2.  A Novel Identified Long Intergenic Noncoding RNA, LINC01574, Contributes to Breast Cancer Deterioration via the Regulation of miR-6745/TTYH3 Axis.

Authors:  Liang Zhang; Lingyuan Wu; Mengjiao Wei; Peikai Ding; Xingsong Tian; Kunbing Zhu
Journal:  J Immunol Res       Date:  2022-07-27       Impact factor: 4.493

3.  LncRNA SNHG6 sponges miR-101 and induces tamoxifen resistance in breast cancer cells through induction of EMT.

Authors:  Mohammad Imran Khan; Aamir Ahmad
Journal:  Front Oncol       Date:  2022-09-23       Impact factor: 5.738

Review 4.  Vitamin D May Protect against Breast Cancer through the Regulation of Long Noncoding RNAs by VDR Signaling.

Authors:  Janusz Blasiak; Jan Chojnacki; Elzbieta Pawlowska; Aleksandra Jablkowska; Cezary Chojnacki
Journal:  Int J Mol Sci       Date:  2022-03-16       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.